PURPOSE: Central @entity2994 (CRVO) often produces significant and permanent @entity1018 in the affected eye. The purpose of this study was to determine if @entity1 with @entity2994 and infusion of @entity3479 ) experienced recovery of visual acuity. DESIGN: Prospective, noncomparative, interventional case series. @entity1 : Thirty eyes of 30 consecutive @entity1 with CRVO underwent the procedure, but two were subsequently excluded. The remaining 28 eyes of 28 @entity1 with CRVO for an average of 4.9 months before intervention (range, 0.25-30 months) and best-corrected visual acuity 20/63 or worse were included in the study. INTERVENTION: All @entity1 underwent pars plana vitrectomy with cannulation and infusion of @entity1456 into a branch retinal vein. MAIN OUTCOME MEASURES: Change in visual acuity and the development of complications such as @entity548 and @entity2297 were monitored. RESULTS: Twenty-two of 28 @entity1 (79%) experienced at least one line of visual improvement during the follow-up period (average, 11.8 months; range, 3-24 months), and the same number had this level of improvement at the last follow-up examination. Fifteen @entity1 (54%) gained 3 or more lines of acuity within 6 months after the procedure, and 14 (50%) had acuity at last follow-up at least 3 lines better than baseline acuity (average, 6.8 lines). Seven @entity1 had postoperative vitreous @entity548 ranging from 1 week to 11 months after the procedure; two cleared spontaneously. One @entity1 had a postoperative @entity1713 from a peripheral retinal break that was repaired successfully with pneumatic retinopexy. No other serious intraoperative or early postoperative complications were noted. CONCLUSIONS: Vitrectomy with retinal vein cannulation and infusion of @entity1456 is a relatively safe procedure that may improve vision in eyes with CRVO.

Injection of @entity1456 into a branch retinal vein in eyes with central XXXX .

@entity1018 :: ('MESH:D054062', 'Disease') :: ['loss of vision'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PARTICIPANTS'] @entity548 :: ('MESH:D006470', 'Disease') :: ['vitreous hemorrhage', 'hemorrhages'] @entity1713 :: ('MESH:D012163', 'Disease') :: ['retinal detachment'] @entity2994 :: ('MESH:D012170', 'Disease') :: ['retinal vein occlusion', 'vision loss secondary to CRVO treated with retinal vein cannulation'] @entity1456 :: ('100128998', 'Gene') :: ['t-PA'] @entity3479 :: ('5327', 'Gene') :: ['tissue plasminogen activator (t-PA'] @entity2297 :: ('MESH:D015355', 'Disease') :: ['neovascular glaucoma']
@entity2994 :: (MESH:D012170,Disease) :: ['retinal vein occlusion']
